Pharma in Focus
Email Address Sign-Up

Australia's most trusted source of pharma news

Buy now fake rolex


Blockbusters win PBS berths

Posted 26 February 2021 PM

Sanofi's blockbuster eczema drug Dupixent has finally been given a PBS greenlight and will be listed from Monday.

After languishing for 12 months following a positive recommendation last March, the biologic will be subsidised for the treatment of patients with chronic severe atopic dermatitis who gained inadequate benefit from topical therapies.

Looks like you've lost your access to Pharma in Focus. To restore access or update your subscription, click here

Top of the Hill
All fine, nothing to see here
How politics made a mess of the rollout
Special Report
PBAC July Agenda
Committee to assess 36 submissions
Approvals Action
First copy of gout drug
Plus new formulations of PBS-listed drugs
Special Report
Aust Covid Vaccine Tracker
UPDATE: Distribution of two mRNA vaccines overseas